Is Ucb SA halal to invest in?

As of July 2026, Ucb SA UCB.VI is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Ucb SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Ucb SA using these criteria to determine its compliance status.

Can Muslims buy shares of Ucb SA?

Muslim investors may consider investing in Ucb SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Ucb SA classified as HALAL?

Musaffa determines the Shariah status of Ucb SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Ucb SA updated?

The Shariah compliance status of Ucb SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Ucb SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Ucb SA?

You can check the latest Shariah compliance status of Ucb SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Ucb SA UCB.VI

Last Updated: Jul 20, 12:00 AM·WBAG

UCB.VI Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Ucb SA is classified as halal.

HALAL

Report Source: 2025 Annual Report

Ucb SA. Stock Analysis UCB.VI

Austria Health Care Large Cap Report: 2025 Annual

UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 10,117 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Shariah Compliance Report

An extensive business and financial screening of the company which specifies why a stock is halal or haram!